Tier 4 — mechanistic

Erratum: Author Correction: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study

Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E
NPJ aging and mechanisms of disease 2018 4; 8

Bibliography

PubMed
PMID 30155270
PubMed Central
PMC6102308
DOI
10.1038/s41514-018-0027-1
Funding
Correction notice; funding information belongs to the original study.
Competing interests
Correction notice; consult the original study’s disclosures.

Study snapshot

DesignPublished correction or corrigendum
ModelPublication correction
SampleNo new participants
InterventionCorrection to the NR/pterostilbene report PMID 29184669
DurationPublished correction
EndpointsCorrection of the linked original publication

What the study showed, in plain terms

The correction repaired a reference and added the previously omitted source of the placebo and NR/pterostilbene products.

Key findings

The correction repaired a reference and added the previously omitted source of the placebo and NR/pterostilbene products.

What this study can and cannot tell us

Supporting notice for the original study, not an independent experiment or new efficacy result.

Related papers in the corpus

Tier 2
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2017
Tier 4
Publisher Correction: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
McDermott MM et al. · Nature communications · 2024
Tier 4
Corrigendum to: 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
et al. · Aging cell · 2022
Tier 4
Corrigendum to "Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm"
et al. · International journal of toxicology · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology